Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses:
“We are delighted to share that CYB003 achieved the primary efficacy endpoint in this study and showed rapid and statistically significant improvements in depression symptoms after a single dose, with a clear incremental benefit of a second dose, resulting in 4 out of 5 patients in remission from their depression at 6 weeks,” said Doug Drysdale, Chief Executive Officer of Cybin. “This is an impressive finding and follows on from the unprecedented interim results we announced earlier this month. Importantly, the strength of the data supports progression to a Phase 3 study of CYB003 for the treatment of MDD.”
New Study Looks at Shame, Guilt, and the Psychedelic Experience
A new study published by a group of researchers, including Matthew Johnson from Johns Hopkins, looks at emotionally painful, shame-related processes with psychedelic use.
Results: Most users (89.7%) described their experience of psilocybin as positive, though acute feelings of shame or guilt were commonly reported (68.2% of users) and were difficult to predict. Psilocybin on average produced a small but significant decrease in trait shame that was maintained 2-3 months after use. Trait shame did increase in a large minority (29.8%) of participants.
Enveric Granted US Patent for Psilocybin Derivatives
“Extensive and multilayered intellectual property for our novel compounds is an important value driver for Enveric as we seek to develop improved treatments for patients living with severe and difficult to treat mental health disorders,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
“This recent positive decision from the USPTO adds to the intellectual property for our EVM301 Series of molecules. These molecules have the potential to change the paradigm of treatment of depression and anxiety disorders. The clinical objective for this class of molecules is to generate therapeutic benefit without inducing the hallmark hallucinations associated with most psychedelic and psychedelic-inspired molecules.”
Filament Health Announces US$14.4 million Funding & Planned NASDAQ Listing
Benjamin Lightburn, Filament CEO and Chairman: “The Company is pleased to announce this term sheet with Helena Partners. The execution of a financing with Helena will provide Filament with significant capital to fund our operations, advance our drug development program, and contribute to cash at the closing of the Proposed Business Combination. We believe that the Financing represents an important de-risking milestone for executing the Proposed Business Combination and our anticipated listing on the Nasdaq.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
